References
- Schweitzer V G, Rarey K. E, Dolon D F, Abrams GE, Sheridan C. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs. CBDCA (JM-8) and CHIP (JM-9). Laryngoscope 1986; 96: 959–74
- Laurell G, Bagger-Sjoback D. Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 1991, in press
- Hayes D M, Cvitkovic E., Golbey RB. High dose cis-platinum diamine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–81
- Black F, Myers O. E, Schramm N. VL. Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope 1982; 92: 1363–8
- Hartwig S, Pettersson U, Startle J. Cis-diaminedichloroplatinum: a cytostatic with an ototoxic effect. ORL 1983; 45: 257–61
- Fleischman R W, Stadnicki S, Ethier W. MF., Schaeppi U. Ototoxicity of cis-dichlorodiamine platinum (II) in the guinea pig. Toxicol AppI Pharmacol 1975; 33: 320–32
- Estrem S A, Babin RW., Ryu J H, Moore KC. Cis-diaminedichloroplatinum (II). Ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 1981; 89: 638–45
- Nakai Y., Konishi K. Chang Ototoxicity of the anticancer drug cisplatin. Acta Otolaryngol (Stockh) 1982; 93: 227–32
- Schweitzer VG., Hawkins J E, Lilly DJ. Ototoxic and nephrotoxic effects of combined treatment with cis-diaminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg 1984; 92: 38–49
- Reddel RR., Kefford R F, Grant JM. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 1982; 66: 19–23
- Vermorken J, Kapteijn B. TS., Hart A AM, Pinedo HM. Ototoxicity of cis-diaminedichloroplatinum (II): Influence of dose schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53–8
- Laurell G., Jungnelius U. High-dose cisplatin treatment. Hearing loss and plasma concentrations. Laryngoscope 1990; 100: 724–34
- Engström H, Ades H N, Andersson A. Structural pattern of the organ of Corti. a systemic mapping of sensory cells and neural elements. Almqvist and Wiksell, Stockholm 1966
- Kommune Asakuma S. A., Snow JB. Pathophysiology of the ototoxicity of cis-diaminedichloroplatinum. Otolaryngol Head Neck Surg 1981; 89: 275–82
- Laurell G, Engstrom B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hear Res 1989; 38: 27–34
- Tasaki I., Spyropoulos CS. Stria vascularis as source of endocochlear potential. J Neurophysiol 1959; 22: 149–55
- Tange R A, Vuzevski VD. Changes in the stria vascularis of the guinea pig due to cis-platinum. Arch Otorhinolaryngol 1984; 239: 41–7
- Stadnicki S W, Fleischman R, Schaeppi U, Merriam P. Cis-dichlorodiamineplatinum (II) (NSD-119875): Hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 1975; 59: 467–80
- Barron S E, Daigneault EA. Effect of cisplatin on hair cell morphology and lateral wall Na. K-ATPase activity. Hear Res 1987; 26: 131–7
- Laurell G., Skedinger M. Changes of stapedius reflex and hearing threshold in patients receiving high-dose cisplatin treatment. Audiology 1990; 29: 252–61